Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05662397 · ClinicalTrials.gov registry record · Phase 1

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

A Phase 1 study of Solid Tumor, Adult and Refractory Cancer, sponsored by HotSpot Therapeutics.

Active
Registry status
Phase 1
Development phase
77
Enrollment target
14
Study locations

NCT05662397 is a Phase 1 study of Solid Tumor, Adult and Refractory Cancer that is active but no longer recruiting, run by HotSpot Therapeutics. The registered enrollment target is 77 participants, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (59% lower). The trial reports 14 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05662397, a Phase 1 study of Solid Tumor, Adult and Refractory Cancer, is active but no longer recruiting, sponsored by HotSpot Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
77 participants
Enrollment target
14
Study locations

Study Summary

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.

Conditions Studied

Solid Tumor, Adult Refractory Cancer Relapsed Cancer

Interventions

  • BIOLOGICAL Cemiplimab
  • DRUG HST-1011

Study Locations (14)

Other

  • NEXT Oncology Barcelona IOB Hospital Quirónsalud - Barcelona
  • Clínica Universidad de Navarra - Madrid
  • NEXT Oncology Hospital Universitario Quirónsalud Madrid - Madrid
  • Clínica Universidad de Navarra (Pamplona) - Pamplona

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • Montefiore Einstein Comprehensive Cancer Center - The Bronx

Pennsylvania

  • Abramson Cancer Center - Philadelphia
  • University of Pittsburgh (UPMC), Hillman Cancer Center - Pittsburgh

Ontario

  • University of Ottawa - Ottawa
  • Princess Margaret Cancer Center - Toronto

Florida

  • Florida Cancer Specialists - Sarasota

Nevada

  • Comprehensive Cancer Centers of Nevada - Las Vegas

Oregon

  • Providence Cancer Institute of Oregon - Portland

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2023-03-15
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

HotSpot Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05662397

The ClinicalTrials.gov registry entry for NCT05662397 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (59% lower). The listed sponsor is HotSpot Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT05662397 reports 14 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05662397 about?

NCT05662397 is a clinical study titled "A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody". This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.

What is the current status of trial NCT05662397?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2023-03-15. Estimated completion is 2026-12-31.

What conditions does trial NCT05662397 study?

This clinical trial studies the following conditions: Solid Tumor, Adult, Refractory Cancer, Relapsed Cancer.

What interventions are being tested in trial NCT05662397?

The interventions under investigation include: Cemiplimab (BIOLOGICAL), HST-1011 (DRUG).

Who is sponsoring clinical trial NCT05662397?

This trial is sponsored by HotSpot Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05662397 being conducted?

This trial has 14 study locations across Florida, Nevada, New York, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

Refractory Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.